What Scalid Treats: Main Uses and Benefits

The primary role of Scalid is to provide symptomatic relief across specific therapeutic domains, focusing on managing symptoms that create noticeable physiological strain and may interfere with functional stability. The medication is applied across domains where additional symptomatic support is needed for acute pain and primary dysmenorrhoea. It is commonly used when short-term symptomatic assistance is needed to address acute and episodic changes.

---

Scalid is generally used in areas where short-term symptom management is appropriate, particularly for conditions presenting with both symptoms related to physical discomfort and symptoms related to inflammatory or irritative states. It helps address symptom clusters that may become intense or disruptive, such as those associated with trauma or minor procedures.

The medication is applied to address symptoms associated with acute or episodic changes, including acute painful states, primary dysmenorrhea (menstrual pain), and osteoarthritis flare-ups. In these scenarios, the medication contributes to improved comfort during periods of heightened symptoms.

It also plays a role in managing symptoms related to systemic imbalance, specifically fever (pyrexia), which often occurs alongside physical discomfort.

Quick Fact: Relief for Acute Discomfort
Typical Contexts: Situations involving acute discomfort, painful joint flare-ups, and symptomatic menstrual cramping.
Benefit Focus: Contributing to easing the overall symptom load during periods of symptomatic discomfort.

Regulatory References

1. European Medicines Agency Nimesulide Referral

Who Can and Cannot Use Scalid? (Nimesulide)

Official regulatory documents define strict criteria for who is eligible to use Scalid (Nimesulide), a drug that is not approved for marketing in the United States by the FDA. Eligibility is primarily restricted based on age, organ function, and pre-existing conditions.

---

Populations Allowed and Prohibited

Eligibility Status	Description
Allowed	Adults and adolescents aged 12 years and older. Use in elderly patients requires caution but is permitted.
Contraindicated	Children under 12 years are formally prohibited from using the medicine.

---

Absolute Contraindications (Must Not Use)

Scalid is formally contraindicated and must not be used by patients with:

• Hepatic impairment (any degree of liver dysfunction).
• Severe renal impairment (creatinine clearance less than 30 ml/min).
• Active gastrointestinal ulceration, a history of recurrent ulcers, or active bleeding (including severe coagulation disorders).
• Severe heart failure or a history of hepatotoxic reactions to Nimesulide.
• Hypersensitivity to Nimesulide, acetylsalicylic acid, or other NSAIDs.

---

Pregnancy and Conditional Use

Use is strictly contraindicated during the third trimester of pregnancy and throughout lactation/breastfeeding. Use is not recommended during the first two trimesters, or for women attempting to conceive. Patients with mild to moderate renal impairment ( CrCl 30-80 ml/min) may use the medicine but require caution.

Interactions with other medicines and products

The official regulatory profile for Scalid (Nimesulide) documents specific interactions with co-administered medicinal products and substances. This information defines constraints based on metabolic, functional, and timing requirements.

Metabolic and Exposure-Altering Interactions

Scalid is documented as an inhibitor of the CYP2C9 enzyme. Co-administration with medicinal products that are substrates of CYP2C9 may result in an increase in their plasma concentrations. Similarly, co-administration with Lithium reduces its renal clearance, leading to elevated plasma levels and potential toxicity. For Methotrexate, caution is required if Scalid is used less than 24 hours before or after treatment, due to the risk of increased serum levels.

Pharmacodynamic and Restricted Combinations

The simultaneous use of Scalid with Anticoagulants (such as Warfarin) is formally not recommended because of the increased risk of bleeding complications. Co-administration with other NSAIDs or analgesics is also not recommended. Scalid reduces the natriuretic and diuretic effect of agents like Furosemide, leading to a decrease in its excretion. Furthermore, the risk of nephrotoxicity may increase when Scalid is combined with Cyclosporines.

Substance and Population-Based Restrictions

Formal restrictions prohibit concomitant exposure to other potentially hepatotoxic substances and require the avoidance of alcohol abuse during treatment due to the heightened risk of hepatic reactions. For renal or cardiac patients, specific caution is advised when co-administering with Diuretics due to the potential for deterioration of renal function.

Inhibition of Cathepsin K (CTSK)

Scalid works by binding to and inhibiting the Cathepsin K (CTSK) enzyme. CTSK is a lysosomal cysteine protease found in osteoclasts, the cells responsible for bone resorption. Scalid demonstrates high selectivity for CTSK, minimizing off-target interaction with related proteases.

---

Cellular Cascade and Physiological Consequence

The inhibition of CTSK results in a reduction of the enzymatic activity required for the hydrolysis and degradation of collagen and other non-collagenous proteins within the bone matrix. This specific molecular intervention modulates the osteoclastic resorption process. The resulting biochemical cascade leads to a reduction in the overall rate of bone matrix breakdown at the system level.

How Scalid is Used: Official Administration Guidelines

Scalid (Nimesulide) is administered according to a specific, short-term usage protocol for its oral and topical forms. The use of this medicine is universally restricted to the shortest possible duration to manage acute symptoms.

---

Systemic Use (Oral Forms)

Administration Detail	Official Guideline
Standard Unit Dose	100 mg per administration for adults and adolescents aged 12 to 18.
Dosing Frequency	The dose is taken twice daily (BID), which constitutes the maximum recommended daily intake of 200 mg.
Timing Constraint	Oral forms must be taken after meals.
Maximum Duration	Systemic treatment is strictly limited to 15 consecutive days.

The 100 mg dose of Scalid establishes a fixed administration regimen for adults. Granules for oral suspension must be reconstituted with water immediately prior to consumption. For patients aged 12 and above, including older adults and those with mild-to-moderate renal impairment, no dosage reduction is generally required from the standard regimen.

---

Topical Use

Scalid is also available as a topical gel for localized application. The gel is typically applied to the affected area two to three times daily, and treatment duration is generally limited to 7 to 15 days. When applying the gel, it must be massaged gently into the skin until fully absorbed, and use with occlusive dressings is not permitted.

Research Evidence / Overview of Studies for Scalid (Nimesulide)

---

Evidence for Use in Acute Pain

The research on Scalid (nimesulide) primarily focuses on studies that examined conditions characterized by outcomes related to physical discomfort, such as acute pain from injuries or minor surgical procedures. Researchers utilized a large volume of short-term, randomized controlled trials (RCTs) and subsequent systematic reviews to monitor how symptoms evolved in observed populations. The findings describe patterns observed in the studies related to the rate of initial observation and the extent of measured change in symptom scores over the first few days of use. Outcomes reported were confined to short-term intervals.

However, the existing body of evidence is strictly focused on very short-term use. Long-term outcomes and the potential for any effects beyond the maximum 15-day treatment period are not well characterized.

---

Evidence for Use in Primary Dysmenorrhoea (Menstrual Pain)

Scalid was evaluated in research exploring primary dysmenorrhoea, which are conditions characterized by fluctuating or episodic manifestations of pain. The main study outcomes monitored were changes in patient-reported intensity of menstrual pain and associated symptoms over the course of the affected menstrual cycles. The research highlights how symptoms evolved during the study period, with findings describing patterns when observed in comparison with other compounds in the same class.

The key research limitation here is that the evidence is derived from studies exploring acute, episodic symptoms. There is limited information for long-term outcomes or for any potential role in addressing symptoms over many years.

---

Research Findings on Restricted or Withdrawn Indications

Historically, Scalid was evaluated in studies examining outcomes related to physical discomfort for chronic conditions like osteoarthritis. Post-marketing and observational analyses subsequently described patterns related to potential severe liver risk associated with longer-term exposure. Subsequent post-marketing evidence was associated with regulatory decisions that restricted its usage to acute episodes only, limiting the duration of treatment significantly.

Key Studies & References

1. Nimesulide in the treatment of primary dysmenorrhea: A double-blind study versus diclofenac (2001)

Common questions about Scalid (FAQ)

---

Q: What is the typical duration of treatment with Scalid?

Official regulatory guidance states that Scalid is intended for use for the shortest possible duration to manage acute symptoms. Treatment is strictly limited to a maximum period of 15 consecutive days. Regulatory constraints specify that treatment must adhere to this maximum duration.

---

Q: Is Scalid safe for use in older adults (seniors)?

While use in older adults is generally permitted, official documentation advises caution. Regulatory safety profiles note that older adults may experience a higher frequency of adverse reactions, particularly serious gastrointestinal events. Due to these documented risks, use in older adults requires close supervision by a healthcare professional.

---

Q: Is the brand name 'Scalid' internationally recognized?

The active ingredient in Scalid, Nimesulide, is widely approved and available for use in many countries globally. However, official information confirms that the active ingredient is not approved for marketing by the U.S. Food and Drug Administration (FDA) in the United States.

---

Q: Why is Scalid sometimes prescribed instead of other similar drugs?

The active ingredient in Scalid is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is noted for its relative selectivity for inhibiting the COX-2 enzyme over the COX-1 enzyme, a characteristic that is described as a factor contributing to its observed anti-inflammatory effects.

---

Q: How quickly can I expect Scalid to start working for my condition?

Official information from studies indicates a relatively rapid onset of action. Clinical studies have observed patterns of symptom reduction beginning shortly after the initial drug intake, aligning with its purpose for treating acute conditions.

---

Q: Is Scalid known to cause extreme tiredness or fatigue?

Official documentation lists fatigue and sleepiness (somnolence) among the possible reported side effects. Furthermore, persistent or unusual fatigue is mentioned as a potential symptom of rare, serious complications, and is one of the symptoms a healthcare provider may monitor for during use.

---

Q: Does Scalid interact with common pain relievers like ibuprofen or acetaminophen?

Regulatory guidance formally advises against co-administration with other nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesics. Official documentation advises against this combination because of a documented increased potential for adverse reactions.

---

Q: Is it safe to take Scalid if I'm already taking supplements like Vitamin D or iron?

Official warnings caution against using Scalid alongside any other potentially hepatotoxic substances (those that can harm the liver). It is standard medical practice for individuals to inform their healthcare provider of all supplements they are taking to assess any possible combination risk.

---

Q: Is there long-term data available on the safety of Scalid?

The body of research evidence for Scalid is strictly focused on very short-term use, aligned with the maximum 15-day treatment restriction. Long-term outcomes and any potential effects beyond this maximum period are not well characterized or documented in the existing evidence base.

---

Q: What happens if I accidentally miss a dose of Scalid?

Patient information commonly instructs that if a dose is missed, and the time for the next scheduled dose is near, the missed dose should generally be skipped. The guidance specifies returning to the regular dosing regime and generally advises against taking a double dose to make up for a missed one.

---

Q: Does taking Scalid make you more sensitive to the sun?

Official regulatory guidance, particularly for the topical gel form, advises caution. It recommends minimizing exposure to direct sun or sunlamps to reduce the risk of photosensitivity reactions while using the medicine.

---

Q: Is Scalid available in different strengths?

The standard unit dose for the oral form is 100 mg. The medicine is also available in forms for application to the skin (topical gel). Official information confirms that different strengths or formulations may be available depending on the specific country's approved product range.

---

Q: Are the side effects of Scalid similar to those of its drug class?

Yes, Scalid belongs to the NSAID class, and its safety profile is aligned with constraints common to this group. Regulatory documents specifically note constraints concerning the gastrointestinal (stomach and intestines) and hepatobiliary (liver) systems, similar to other NSAIDs.

---

Q: Is there a risk of becoming dependent on Scalid?

Official regulatory documents do not classify the active ingredient in Scalid as a controlled substance. It is not generally associated with dependency or abuse risk in the authoritative medical literature.

---

Q: Are there any common lab tests required while taking Scalid?

Due to the potential for rare but serious liver toxicity, official guidance advises monitoring of liver function tests during treatment. This monitoring is specifically advised when the drug is used in combination with other substances that may affect the liver.

---

Q: Does Scalid interact with oral contraceptives (birth control pills)?

The drug is known to inhibit the CYP2C9 enzyme, which is involved in metabolizing certain medications. Some authoritative sources have suggested that co-administration with oral contraceptives may require monitoring by a healthcare provider due to the potential for increased risk of liver damage.

---

Q: Are there any dietary restrictions mentioned in the official guidance for Scalid?

Official restrictions require the avoidance of alcohol abuse during the period of treatment. While oral forms are directed to be taken after meals, regulatory guidance does not formally restrict specific food items other than alcohol.

---

Q: Can Scalid be taken alongside common cold and flu medicines?

Regulatory guidance formally advises against the co-administration of Scalid with other NSAIDs or analgesics. Since many common over-the-counter cold and flu preparations contain these same active ingredients, medical guidance often formally restricts concomitant use.

---

Q: Does Scalid affect mental clarity or concentration?

Official information lists dizziness and somnolence (sleepiness) as uncommon side effects. Official warnings describe that if patients experience these effects, regulatory guidance advises avoiding driving or operating machinery.

---

Q: Is there a patient leaflet or guide for Scalid available online?

Yes, the Patient Information Leaflet (PIL) and the more detailed Summary of Product Characteristics (SmPC) for the active ingredient are typically made publicly available. These documents can usually be found on the websites of national regulatory bodies that have approved the medicine.

How to Store and Dispose of Scalid?

Official regulatory guidelines define specific requirements for the storage, protection, and disposal of this medicine, ensuring the integrity and safety of the product.

Storage Requirement	Official Mandate
Temperature & Environment	Store at room temperature and protect from both moisture and light.
Packaging	Keep the medicine in its original container or outer carton until the time of use.
Prohibitions	Do not freeze or refrigerate the product.

Disposal and Safety Rules

The most important safety rule is the mandatory instruction to keep Scalid out of the sight and reach of children at all times. Regarding disposal, regulatory authorities mandate that the medicine must not be disposed of in household waste or wastewater (e.g., sink or toilet). Instead, unused or expired Scalid must be discarded through an approved pharmaceutical take-back program or returned to a local pharmacy for proper environmental handling, as required by local regulations.